· Two patients at DL4 continue to respond at 5+ months (1 PR and 1SD) · One patient at DL3 had PR until month8. *Presented by Schoenfeld et al. at the IASLC 2025 World Conference on Lung Cancer ; September 69,2025 investigator-initiated trials. We plan to use data from investigator-initiated clinical trials to priori